1. Introduction {#s0005}
===============

Schizophrenia is a chronic psychiatric disease that disturbs perception of reality and one\'s interpersonal relationships, and it has a prevalence of 1% in the population. Cognitive decline by progression of the disease is one of the strongest predictors of functional abilities ([@bb0015]; [@bb0095]; [@bb0135]). Low prefrontal activity is evident in schizophrenia by neuroimaging studies ([@bb0230]). Attention, working memory and executive functions which are among important cognitive functions of prefrontal cortex have been firmly reported as impaired in schizophrenia ([@bb0070]; [@bb0120]; [@bb0180]).

Attention is a set of functions that provides recognition of the stimulus (detection), selectively focusing on the stimulus (selective attention), pursuing of attention on the stimulus (sustained attention) and transferring of the stimulus for more advanced processes, and is critically important in information processing ([@bb0240]). Working memory which can be defined as the ability to store and manipulate information online, is a process that underlies several dimensions of cognitive functions such as language comprehension, learning and reasoning ([@bb0015]; [@bb0235]). Executive functions refer to a set of cognitive processes including attentional control, inhibitory control, working memory, and cognitive flexibility, as well as reasoning, problem solving, and planning that are necessary for the cognitive control of behavior.

The dorsolateral prefrontal cortex (DLPFC) is an important brain area mostly involved in attention, working memory and executive functions. Decreased DLPFC activity is thought to result in deterioration of these functions ([@bb0030]; [@bb0220]). Hence, in this study, we used Wisconsin Card Sorting Test (WCST), Digit Span Task (DST) and Stroop Test (ST) to assess DLPFC activity ([@bb0055]; [@bb0165]).

Wisconsin Card Sorting Test is used as a tool to measure executive functions ([@bb0100]). It requires strategic planning, organized searching, utilizing environmental feedback to shift cognitive sets, directing behavior towards achieving a goal and modulating impulsive responding. The Stroop Test assesses the ability to inhibit cognitive interference, occurring when the processing of a stimulus feature affects the simultaneous processing of another attribute of the same stimulus ([@bb0245]). It is also reported that ST can measure some other cognitive functions such as attention, processing speed, and working memory ([@bb0140]; [@bb0245]). Digit Span Task is a task consisting of two main conditions; forward and backward. It mainly measures attention, short term memory and verbal working memory ([@bb0045]; [@bb0145]; [@bb0210]).

Although it is evident that antipsychotic drugs are effective on positive symptoms, they do not have a major effect on cognition, in schizophrenia. Therefore, new treatment modalities are needed to be searched for cognitive loss in schizophrenia ([@bb0050]; [@bb0060]; [@bb0080]; [@bb0125]). Repetitive transcranial magnetic stimulation (rTMS), hence, may be a new line treatment modality for such a goal ([@bb0015]; [@bb0255]). rTMS delivers whether low or high frequency trains of magnetic stimuli to the cortical region of interest to induce changes in the function of that area. As it has a central role in attention, working memory and executive functions, DLPFC, has been a target for rTMS practices. In a neuroimaging study with perfusion SPECT on healthy people, 20 Hz rTMS targeted the left DLPFC region has been resulted in increased blood flow in dorsolateral prefrontal, anterior cingulate and orbitofrontal cortices ([@bb0065]). With high frequency rTMS on DLPFC, although, some studies reported an improvement in selective attention ([@bb0170]; [@bb0205]), some found no difference of cognitive functions ([@bb0025]; [@bb0105]; [@bb0270]). In another study, Barr et al. have shown a significant improvement in working memory by applying bilateral 20 Hz rTMS on DLPFC sequentially ([@bb0015]). Thus, rTMS targeting on DLPFC may be expected to display a positive effect on cognitive functions in schizophrenia.

The main objective of this 4-week randomized double-blind sham-controlled study is to investigate the effect of bilateral 20 Hz rTMS on attention, working memory and executive functions in schizophrenia patients.

2. Materials and methods {#s0010}
========================

The research protocol was approved by Şişli Hamidiye Etfal Training and Research Hospital Ethic Board in accordance with the Declaration of Helsinki. The approval of the study was granted by the Institutional Ethics Committee (Şişli Hamidiye Etfal Training and Research Hospital, decision no: 558/2013).

2.1. Subjects {#s0015}
-------------

In this study, subjects with schizophrenia were recruited from Şişli Hamidiye Etfal Training and Research Hospital (İstanbul, Turkey) for six months (between January and July 2014). Age, sex and education-matched right-handed healthy subjects were randomly recruited by face to face interview from Şişli area that the hospital locates. They were screened with Symptom Check List-90-Revised (SCL-90-R) questionnaire, and subjects having a Global Severity Index (GSI) score of \<1.0 were included ([@bb0150]). Right-handed subjects with schizophrenia between 18 and 65 years old were recorded. In order to exclude a probable comorbid cognitive disorder, the patients performed the Turkish version of Standardized Mini Mental Test (SMMT), and those having a score of 24 or more from SMMT have been included in the study ([@bb0075]). To exclude depression, which is another psychiatric disorder that may disrupt cognitive functions, the patients who has the Calgary Depression Scale for Schizophrenia (CDS) score of 11 or less have been included ([@bb0005]). Also, because antipsychotics may cause some extrapyramidal side effects resulting in deceleration of cognitive functions and motor velocity, and because that might affect patients\' test performance, those who have a score of 2 (which means that the patient has a mild side effect) or lesser for each item of Extrapyramidal Symptoms Rating Scale (ESRS) were included. Subjects with schizophrenia were excluded if they have any comorbid psychiatric disorder according to Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I), any major neurological (cerebrovascular disease, brain trauma or tumor, encephalitis or meningitis, epilepsy, multiple sclerosis etc.) or medical (diabetes mellitus, hypothyroidism, any infection, hypovitaminoses like B12 or folate deficiencies, myocardial infarction etc.) disease, as well as those with pregnancy, having a cardiac pacemaker or any metal implant. Additionally, because WCST and ST performances require to discriminate colors correctly, color blindness of all participants was excluded. All subjects provided their informed written consent. Inclusion of all subjects rested on volunteering and no payment were done.

2.2. Clinical assessment {#s0020}
------------------------

Diagnoses were confirmed with SCID-I before the study entry. Symptom severity in schizophrenia patients have been measured with the Positive and Negative Syndrome Scale (PANSS) and Scale for the Assessment of Negative Symptoms (SANS) by a psychiatrist at the day before the first rTMS session and the following day after the 20th session. To assess cognitive functions, subjects with schizophrenia performed WCST, DST and ST at the day before the first rTMS session and at the following day after the last session. Healthy subjects performed the same tests for once. They were control comparison of cognitive status with each of schizophrenia group.

2.3. Randomization and masking {#s0025}
------------------------------

The subjects with schizophrenia were randomized as an active and sham group. They were randomly assigned (1:1) sequentially (first active and then sham). The order of DLPFC hemispheric stimulation was also randomized sequentially (1:1) and counterbalanced (left then right DLPFC followed by right then left DLPFC in each group). In order to prevent any interaction between the patients, we avoided selecting patients who might have any personal relationship with each other. Their appointments for rTMS sessions were organized on remote times. The subjects and the experimenter were masked to the treatment conditions during the study.

2.4. rTMS protocol {#s0030}
------------------

Subjects with schizophrenia received a total of 20 sessions of rTMS treatment, during the 5 week days. They were excluded from the study if they missed \>4 sessions of treatment, including weekend days. The rTMS was administered with a Magstim stimulator (Magstim Company Ltd. Whitland, UK), 70-mm diameter figure-of-eight coil sequentially to bilateral DLPFC at 20 Hz, 90% resting motor threshold for 20 trains, 50 pulses/train, inter-train interval of 20 s (1000 pulses/hemisphere, a total of 2000 pulses/session/day) in accordance with safety guidelines ([@bb0035]; [@bb0215]). The order of bilateral stimulation (i.e., left then right or right then left) was constant for all 20 treatments. The resting motor threshold was defined as the lowest intensity that produced a motor evoked potential of at least 50 mV in 50% of the trials delivered. It was determined with the minimum motor threshold value method which produces contractions in the abductor pollicis brevis muscle in at least 5 out of 10 sequential single stimulus applications on the area corresponding to the motor cortex. The site of stimulation during the rTMS treatment sessions was defined by a point 5 cm anterior to that required for maximum stimulation of the abductor pollicis brevis muscle for each hemisphere ([@bb0190]). The subsequent hemisphere was stimulated just after the stimulation of the first hemisphere. Sham stimulation was delivered at the same parameters with the coil held in a single wing-tilt position at 90 degrees, inducing similar somatic sensations as in the active stimulation with no major brain effects. The study treatment was found to be safe and well tolerated.

2.5. Statistical analysis {#s0035}
-------------------------

The data was analyzed by Statistical Package for Social Sciences (SPSS for Windows 17.0, SPSS Inc., IL, ABD) computer program. Neuropsychological variables were tested for assumptions of normality (Shapiro--Wilk test) and homogeneity of variances. Descriptive data of all groups has been determined. Differences in demographic and clinical data between the groups were compared with chi-square test for categorical data and independent *t*-test for continuous data. Initially, to test relevance of the groups\' data with literature, baseline neuropsychological status between three groups (healthy, active rTMS and sham rTMS) have been compared by One-Way ANOVA test. Comparison of test scores (before treatment, and after treatment) between the schizophrenia groups (active vs. sham) has been done by using independent *t*-test or Mann-Whitney *U* test. Intragroup changes of test scores have been analyzed by paired-samples *t*-test or Wilcoxon test. Effect size measured by Cohen\'s d. The level of significance *p* was assumed to be below .05.

3. Results {#s0040}
==========

3.1. Patient data {#s0045}
-----------------

In this study, 21 (11:10; active:sham) subjects with schizophrenia and 11 healthy control subjects were analyzed. Subject selection and randomization diagram is shown in the [Fig. 1](#f0005){ref-type="fig"}. A total of 41 subjects with schizophrenia were recorded. 17 of them did not matched all the criteria, so only 24 subjects have been included. A female subject with schizophrenia had to leave the study at 17th session of the treatment because of a holiday plan with her family, two ones from the sham group left the study at 3rd and 16th sessions relatively, because of their disbelief about the efficiency of the treatment. Ethically, none of patients\' medication was changed during the study. Patients who may need a major medical treatment change were also excluded.Fig. 1Flow diagram.Fig. 1

Demographic and clinical data is given in [Table 1](#t0005){ref-type="table"}. There was no significant difference between the healthy control group and each schizophrenia treatment group, in terms of age (*p* = .857), gender (*p* = .725) and total years of education (*p* = .984). To assess severity of the illness, the mean duration of illness (*p* = .078), total number of inpatient treatments (*p* = .476), type (typical vs. atypical; *p* = .648) and chlorpromazine equivalent doses of antipsychotic drugs (*p* = .318), and baseline PANSS and SANS total scores (respectively; *p* = .568 and *p* = .144) of schizophrenia treatment groups were not significantly different ([@bb0260]).Table 1Demographic and clinical data.Table 1Healthy (n = 11)Active (n = 11)Sham (n = 10)*p*Mean age (years)36.55 ± 8.8036.45 ± 8.5834.40 ± 12.11.857Gender (M/F)8/38/36/4.725Mean years of education, n10.64 ± 1,5010.73 ± 1.6110.60 ± 1.89.984Mean duration of illness (months)--184.55 ± 97.51133.10 ± 120.77.078Number of inpatient treatments--4.64 ± 4.243.50 ± 3.44.476PANSS/SANS scores--81.82 ± 8.94/52.64 ± 13.1479.70 ± 7.61/43.10 ± 15.50.568/.144Chlorpromazine equivalent dose of antipsychotic drugs (mg)--845.45661.66.318Type of antipsychotic drug (typical vs. atypical)--Typical = 1\
Atypical = 8\
Both = 2Typical = 0\
Atypical = 8\
Both = 2.648Medication, n: dose (mg) Haloperidol--n = 2 (20 mg/day, 50 mg/week dekanoat)n = 1 (10 mg/day) Zuclopentixol--n = 1 (200 mg/2 week depot)-- Flupentixol----n = 1 (20 mg/2 week depot) Chlorpromazine--n = 1 (100 mg/day)-- Risperidone--n = 4 (2 × 3 mg/day, 2 × 50 mg/2 week consta)n = 3 (2 mg/day, 2 × 50 mg/2 week consta) Paliperidone----n = 3 (6 mg/day, 100 mg/4 week and 150 mg/4 week injection) Amisulpiride--n = 1 (800 mg/day)-- Clozapine--n = 2 (2 × 600 mg/day)n = 4 (2 × 200 mg/day, 400 mg/day, 500 mg/day) Olanzapine--n = 2 (10 mg/day, 15 mg/day)n = 1 (5 mg/day) Quetiapine--n = 5 (3 × 300 mg/day, 400 mg/day, 600 mg/day)n = 2 (50 mg/day, 300 mg/day) Aripiprazole--n = 2 (2 × 30 mg/day)n = 3 (15 mg/day, 2 × 30 mg/day)[^1]

3.2. Test performance changes {#s0050}
-----------------------------

### 3.2.1. Baseline test scores {#s0055}

Comparison of baseline test scores of all the three groups (control vs. each schizophrenia treatment group) are summarized in [Table 2](#t0010){ref-type="table"}. Almost all the baseline neuropsychological test mean scores of each schizophrenia treatment group (active/sham rTMS) were poorer comparing with the healthy group, but not all were significant.Table 2Comparison of baseline test scores between healthy control group and each of schizophrenia treatment group.[a](#tf0005){ref-type="table-fn"}Table 2PerformanceActive (n = 11)Healthy (n = 11)Sham (n = 10)WCST scores (*p*) Total trials administered1.0000.717 Correct responses**0.0430.001** Incorrect responses**0.0360.003** Perseverative responses0.266**0.039** Perseverative errors0.159**0.027** Nonperseverative errors0.0920.127 % of perseverative errors0.156**0.018** Categories**0.0050.009** Trials to complete the first category0.8060.513 % of conceptual level responses**0.0120.002** Failure to maintain set0.4000.974 Learning to learn0.4930.651ST scores (*p*) Total time**0.0070.006** Total errors1.0000.453 Interference0.060**0.027**DST scores (*p*) Forward span0.4620.120 Backward span0.555**0.020**[^2][^3][^4]

### 3.2.2. Comparison of pre- and post-treatment test scores {#s0060}

There was no significant difference in pre-treatment WCST, ST and DST scores between rTMS groups (*p* \> .05). Indeed, post treatment *ST total time* (*p* = .045; *Cohen\'s d* = 0.94), *ST total errors* (*p* = .44; *Cohen\'s d* = 0.95) and *interference* (*p* = .021; *Cohen\'s d* \> 1.00) scores of active rTMS group were significantly better than sham (see [Table 3](#t0015){ref-type="table"}). Accordingly, post-treatment *DST forward span* (*p* = .045; *Cohen\'s d* \> 1.00) and *DST backward span* (*p* = .042; *Cohen\'s d* = 0.98) scores of active rTMS group were significantly better (See [Table 4](#t0020){ref-type="table"}).Table 3Comparison of pre- and post-treatment ST scores in between schizophrenia treatment groups.Table 3PerformanceActive (n = 11)Sham (n = 10)*pCohen\'s d*Pre-treatment\
ST scores Total time[a](#tf0010){ref-type="table-fn"} (mean ± SD)208.31 ± 40.89210.34 ± 30.55.899 Total errors[b](#tf0015){ref-type="table-fn"} (mean ± SD; median)1.09 ± 2.46 (0)4.00 ± 7.10 (5).154 Interference[a](#tf0010){ref-type="table-fn"} (mean ± SD)60.307 ± 23.4164.09 ± 16.29.680[a](#tf0010){ref-type="table-fn"}Post-treatment\
ST scores Total time[a](#tf0010){ref-type="table-fn"} (mean ± SD)177.32 ± 22.52202.22 ± 30.29**.0450.94** Total errors[b](#tf0015){ref-type="table-fn"} (mean ± SD; median)0.45 ± 1.21 (0)2.60 ± 2.98 (2)**.0440.95** Interference[a](#tf0010){ref-type="table-fn"} (mean ± SD)44.44 ± 10.3361.08 ± 19.02**.021\>1.00**[^5][^6][^7][^8]Table 4Comparison of pre- and post-treatment DST scores between schizophrenia treatment groups.[a](#tf0020){ref-type="table-fn"}Table 4PerformanceActive (n = 11)Sham (n = 10)*pCohen\'s d*Pre-treatment\
DST scores DST forward (mean ± SD; median)5.73 ± 0.90 (6)5.30 ± 1.05 (5).269 DST backward (mean ± SD; median)4.00 ± 0.63 (4)3.40 ± 0.96 (4).125Post-treatment\
DST scores DST forward (mean ± SD; median)5.91 ± 0.94 (6)5.10 ± 0.56 (5)**.045\>1.00** DST backward (mean ± SD; median)4.36 ± 0.50 (4)3.70 ± 0.82 (4)**.0420.98**[^9][^10][^11]

### 3.2.3. Changes of Test Scores {#s0065}

There was no significant change in WCST scores in both of the treatment groups (*p* \> .05). Furthermore, test performance of active rTMS group not significantly regressed after the treatment. In Stroop Test, there were significant improvements in both *ST total time* (*p* = .008; *Cohen\'s d* = 0.99) and *interference* (*p* = .013; *Cohen\'s d* = 0.90) scores of active rTMS group, while no improvement in sham group was determined respectively (*p* \> .05). Similarly, improvement in both DST forward and backward scores have been detected in active rTMS group but not sham, while it was significant only in DST backward score change (*p* = .046; *Cohen\'s d* = 0.72: See [Table 5](#t0025){ref-type="table"}).Table 5Intra-group changes in ST and DST scores in active rTMS group.Table 5PerformanceTimeTest score (mean ± SD; median)*pCohen\'s d*ST scores ST total time[a](#tf0025){ref-type="table-fn"}Pre-treatment208.31 ± 40.89 (194.39)**.0080.99**Post-treatment177.32 ± 22.52 (171.08) ST total errors[b](#tf0030){ref-type="table-fn"}Pre-treatment1.09 ± 2.46 (0).414Post-treatment0.45 ± 1.21 (0) Interference[a](#tf0025){ref-type="table-fn"}Pre-treatment60.37 ± 23.41 (57.89)**.0130.90**Post-treatment44.44 ± 10.33 (41.39)DST scores DST forward[b](#tf0030){ref-type="table-fn"}Pre-treatment5.73 ± 0.90 (6).480Post-treatment5.91 ± 0.94 (6) DST backward[b](#tf0030){ref-type="table-fn"}Pre-treatment4.00 ± 0.63 (4)**.0460.72**Post-treatment4.36 ± 0.50 (4)[^12][^13][^14][^15]

4. Discussion {#s0070}
=============

In this study, we have found that 20 Hz repetitive transcranial magnetic stimulation targeted to bilateral dorsolateral prefrontal cortices of subjects with schizophrenia does not has any positive effect on some executive functions such as planning, abstract reasoning, concept formation, set maintaining and set shifting ([@bb0110]), but it may improve attention, verbal working memory, the competence of switching the perceptional set up under a disruptive effect towards new instructions, and processing speed of information.

First of all, there was no significant change in WCST scores in each rTMS group with the treatment (*p* \> .05). Furthermore, test performance of active rTMS group not significantly regressed after the treatment. Theoretically, it is evident that WCST performance is biologically mediated by a neural network extending from dorsolateral prefrontal and orbitofrontal cortices to striatum and thalamus and then turning back to prefrontal cortex thus called 'cortico-striato-thalamo-cortical loop' or salience network ([@bb0195]). Impaired executive functions in schizophrenia are thought to be related to a defect in this network ([@bb0200]). Although, it may be theorized that high frequency rTMS application to dorsolateral prefrontal cortices must improve executive functions by leading to an increased activity in that area, we have not investigated that in our study, indeed. That may be because WCST is a complicated test that needs activation of not only a single brain area but multiple cortical and subcortical areas ([@bb0020]). In a neuroimaging study of WCST on healthy people, there was an increased activity during the feedback phase but not at the sorting phase. Subsequently, with a 20 Hz rTMS (250 ms) intervention during feedback phase, an impairment of WCST performance has been observed, whereas there was no change when given during sorting, set maintaining and set shifting phases ([@bb0130]). That means firing dorsolateral prefrontal cortex by high frequency rTMS may change some WCST subtest scores, but not all. That may rationalize our findings, and may propose that in order to improve WCST performance, it may not be sufficient to simply increase DLPFC activity. More recent studies with similar evidence have been carried out ([@bb0085]; [@bb0175]).

In our study, post treatment *ST total time* and *interference* scores of active rTMS group were better than sham, and there were significant improvements in both *ST total time* and *interference* scores after the treatment. These results led us to hypothesize that application of 20 Hz frequency rTMS to bilateral dorsolateral prefrontal cortices may improve Stroop performance as it increases the competence of switching the perceptional set up under a 'disruptive effect' towards new instructions, and it increases processing speed of information. In Cho and Strafella\'s study on healthy subjects, they gained PET scans of brain activities of the subjects after applying 10 Hz rTMS targeted to their bilateral DLPFC sequentially. During the rTMS application to right DLPFC, they did not observed any regional brain activity increase, whereas dopaminergic activity of ipsilateral orbitofrontal cortex (OFC) and anterior cingulate cortex (ACC) had increased when applying to left DLPFC ([@bb0040]). This increase in dopaminergic activity at OFC and ACC was attributed to the dopaminergic discharge of the neurons extending from ventral tegmental area (VTA) to medial prefrontal cortex via mezocortical tracts caused by rTMS firing of the glutamatergic neurons extending from prefrontal cortex to VTA. Besides this, considering dense connections of DLPFC with OFC and ACC, another presumption was that firing these local dopaminergic neurons by rTMS could lead to such a result. Furthermore, some previous studies carried out with schizophrenia patients revealing the relationship between impaired Stroop performance seen with disconnections at ACC ([@bb0250]; [@bb0265]) may support this suggestion. Moreover, as Stroop Test, which schizophrenia patients have poorer performance may be an indicator of cognitive flexibility ([@bb0160]), it also can be proposed that high frequency rTMS may improve cognitive flexibility in schizophrenia.

Digit Span Task is a well-known neuropsychological task that schizophrenia patients have lower performance than normal population ([@bb0060]). In this study, it is evident that rTMS has positive effects on DST forward and backward scores which may stand for that it improved attention and verbal working memory of schizophrenia patients. As DST forward performance is assumed to be related to attention and short term memory, there was a non-significant improvement in active rTMS group performance despite the deterioration in sham rTMS group. On the other hand, DST backward scores which is mostly related to verbal working memory, had significantly ameliorated in active rTMS group but not in the sham. In a study, regarding a relation between DST performance and right DLPFC, Aleman had found that repetitive transcranial magnetic stimulation over the right dorsolateral prefrontal cortex disrupted digit span task performances of healthy subjects ([@bb0010]). Similarly, in studies with depression no beneficial effect of rTMS on DST performance could be indicated ([@bb0155]; [@bb0185]; [@bb0225]). However, Barr et al. achieved an improvement of working memory in subjects with schizophrenia by applying 20 Hz (750 pulses/side) rTMS on bilateral DLPFC. Moreover, as working memory was measured by n-back task in that study, 3-back task scores of active rTMS group and healthy subjects were non-significantly different ([@bb0015]). In addition, in a recent meta-analysis investigated effect of high frequency rTMS on neurocognitive functions, authors concluded that high frequency rTMS over left DLPFC with a total of pulses \<30,000 could significantly improve working memory in schizophrenia patients ([@bb0115]). As a result, we have found that 20 Hz rTMS has positive effect on both DST forward and backward scores which implies an improvement in attention and verbal working memory in subjects with schizophrenia ([@bb0090]).

There are some limitations of this study. First of all, the mean years of education in our sample was relatively high (\>10 years), so that we cannot allege the same findings for other samples with lesser mean years of education. In addition, although the schizophrenia treatment groups were similar in our sample, the study was carried out in a unique centre and with a relatively small sample. Indeed, in spite of these limitations, the findings were strongly significant. That means the effect might not be related to sample size. Nonetheless, this study must be replicated in a larger sample.

Consequently, bilateral high (20 Hz) frequency repetitive transcranial magnetic stimulation targeted to bilateral dorsolateral prefrontal cortices of schizophrenia patients does not has any positive effect on some executive functions such as planning, abstract reasoning, concept formation, set maintaining and set shifting. However, it may improve attention, verbal working memory, the competence of switching the perceptional set up under a disruptive effect towards new instructions, and processing speed of information in schizophrenia patients. Future studies with longer treatment duration and larger number of patients are needed.

5. Conclusions {#s0075}
==============

To conclude, the main finding of this study is that 20 Hz repetitive transcranial magnetic stimulation of bilateral dorsolateral prefrontal cortices of schizophrenia patients does not has any positive effect on some executive functions such as planning, abstract reasoning, concept formation, set maintaining and set shifting, but indeed, it may improve attention, verbal working memory, the competence of switching the perceptional set up under a disruptive effect towards new instructions, and processing speed of information.
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